Encision Deregisters Common Stock

Medical device company cites high costs and compliance demands as reasons for deregistration.

Jan. 29, 2026 at 8:39am

Got story updates? Submit your updates here. ›

Encision Inc., a medical device company that owns patented Active Electrode Monitoring (AEM) Technology, announced that its Board of Directors has approved the filing of a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock. The company cited the high costs and demands on management's time of ongoing SEC and Sarbanes-Oxley reporting requirements as the primary reasons for this decision.

Why it matters

Deregistration will allow Encision to avoid the significant compliance costs and administrative burdens associated with being a publicly traded company, which the firm believes will provide considerable cost savings. However, it also means the company's reporting obligations and transparency to shareholders will be reduced.

The details

Encision expects the deregistration to become effective 90 days after filing the Form 15. At that point, the company's reporting obligations, including filing annual and quarterly reports, will be suspended. Encision intends to continue publishing unaudited quarterly and annual financial results, and its common stock is expected to continue trading over-the-counter under the ticker 'ECIA', though a maintained trading market is not guaranteed.

  • Encision's Board of Directors approved the deregistration on January 29, 2026.
  • Encision plans to file the Form 15 with the SEC on or about January 29, 2026.
  • The deregistration is expected to become effective 90 days after the Form 15 filing.

The players

Encision Inc.

A medical device company that owns patented Active Electrode Monitoring (AEM) Technology, which prevents dangerous radiant energy burns in minimally invasive surgery.

Robert Fries

The CEO of Encision Inc.

Got photos? Submit your photos here. ›

What they’re saying

“The Company's decision to deregister was made after careful consideration of the advantages and disadvantages, and considering our size and market capitalization, and the high costs and demands on management's time of our ongoing compliance with SEC and Sarbanes-Oxley reporting requirements. We expect to recognize considerable cost savings associated with this decision.”

— Robert Fries, CEO (Press Release)

What’s next

Encision plans to file the Form 15 with the SEC on or about January 29, 2026, and the deregistration is expected to become effective 90 days after the filing.

The takeaway

Encision's decision to deregister its common stock highlights the significant compliance costs and administrative burdens that publicly traded companies, even smaller ones, face. While this move will provide cost savings for Encision, it also means reduced transparency and reporting obligations for shareholders.